CXCL1 and myeloproliferative neoplasm: Our study of all MPN subtypes comprising 146 ET patients, was the first to be sufficiently powered to identify ET-specific differences in GRO-α, EGF, and eotaxin levels and clearly demonstrates their dysregulation in ET patients.